217 related articles for article (PubMed ID: 18509356)
1. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.
Deng H; Tang N; Stief AE; Mehta N; Baig E; Head R; Sleep G; Yang XZ; McKerlie C; Trudel S; Stewart AK; McCart JA
Leukemia; 2008 Dec; 22(12):2261-4. PubMed ID: 18509356
[No Abstract] [Full Text] [Related]
2. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
3. Next-generation oncolytic vaccinia vectors.
Thorne SH
Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
[TBL] [Abstract][Full Text] [Related]
4. Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma.
Lei W; Wang S; Xu N; Chen Y; Wu G; Zhang A; Chen X; Tong Y; Qian W
Biomed Pharmacother; 2020 May; 125():110030. PubMed ID: 32187960
[TBL] [Abstract][Full Text] [Related]
5. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.
Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W
Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
7. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
9. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
10. [Oncolytic poxviruses].
Kochneva GV; Sivolobova GF; Iudina KV; Babkin IV; Chumakov PM; Netesov SV
Mol Gen Mikrobiol Virusol; 2012; (1):8-15. PubMed ID: 22702138
[TBL] [Abstract][Full Text] [Related]
11. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
[TBL] [Abstract][Full Text] [Related]
12. Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.
Jonas BA
Sci Transl Med; 2017 Apr; 9(386):. PubMed ID: 28424330
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
14. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver.
Zimmermann M; Weiland T; Bitzer M; Lauer UM
Methods Mol Biol; 2012; 806():121-36. PubMed ID: 22057449
[TBL] [Abstract][Full Text] [Related]
15. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
16. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A; Hashim L; Faisal MS; Haider MZ; Ahmed Z; Ahmed TF; Shahzad M; Ansar I; Ali S; Aslam MM; Anwer F
Expert Rev Hematol; 2021 Dec; 14(12):1071-1083. PubMed ID: 34428997
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virotherapy for multiple myeloma.
Stief AE; McCart JA
Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
[TBL] [Abstract][Full Text] [Related]
18. Deletion of
Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
[TBL] [Abstract][Full Text] [Related]
19. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
20. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
